NRx Pharmaceuticals, Inc. (NRXP): Price and Financial Metrics
NRXP Price/Volume Stats
| Current price | $3.04 | 52-week high | $12.00 |
| Prev. close | $3.02 | 52-week low | $2.21 |
| Day low | $3.00 | Volume | 233,600 |
| Day high | $3.25 | Avg. volume | 180,654 |
| 50-day MA | $4.88 | Dividend yield | N/A |
| 200-day MA | $3.80 | Market Cap | 29.09M |
NRXP Stock Price Chart Interactive Chart >
NRx Pharmaceuticals, Inc. (NRXP) Company Bio
NRX Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company specializes in researching investigational medicines and is engaged in the development of medicines and vaccines for Covid-19, other respiratory conditions, suicidal depression, and PTSD.
Latest NRXP News From Around the Web
Below are the latest news stories about NRX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NRXP as an investment opportunity.
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of DirectorsNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that Janet Rehnquist has been elected to the Company's Board of Directors where she will chair the compliance and the nominating committees. |
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal DepressionNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it has signed a License Data and Technical Information Agreement with Columbia University for rights to data from a randomized, active-controlled trial of 80 patients hospitalized for Acute Suicidality in Depression. This represents NRx's second well-controlled trial demonstrating the efficacy of IV Ketamine in this indication. |
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract InfectionsNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that its Investigational New Drug Application (IND) for the use of NRX-101, the company's patented combination of D-cycloserine and lurasidone, for the treatment of complicated Urinary Tract infections (cUTI), received clearance from the US FDA. |
NRx Pharmaceuticals Provides Notice of Annual Meeting of ShareholdersNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, announced their 2023 Annual Meeting of Stockholders (the "Annual Meeting") to be held on December 19, 2023, at 11:00 a.m., Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/am2023. |
NRx Pharmaceuticals to Participate in LifeSci Corporate Access EventNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco. |
NRXP Price Returns
| 1-mo | -39.81% |
| 3-mo | -28.44% |
| 6-mo | 7.50% |
| 1-year | -49.33% |
| 3-year | -99.05% |
| 5-year | -97.07% |
| YTD | -33.91% |
| 2023 | -58.56% |
| 2022 | -76.78% |
| 2021 | -80.41% |
| 2020 | 130.19% |
| 2019 | 3.92% |
Loading social stream, please wait...